CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients

Ilhan Tahrali; Umut Can Kucuksezer; Nilgun Akdeniz; Ayse Altintas; Ugur Uygunoglu; Esin Aktas-Cetin; Gunnur Deniz

doi:10.1016/j.imlet.2019.10.006

CD3^-CD56⁺ NK cells display an inflammatory profile in RR-MS patients

Immunol Lett. 2019 Dec:216:63-69. doi: 10.1016/j.imlet.2019.10.006. Epub 2019 Oct 4.

Authors

Ilhan Tahrali¹, Umut Can Kucuksezer¹, Nilgun Akdeniz¹, Ayse Altintas², Ugur Uygunoglu³, Esin Aktas-Cetin¹, Gunnur Deniz⁴

Affiliations

¹ Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology, Istanbul, Turkey.
² Koc University, Faculty of Medicine, Department of Neurology, Istanbul, Turkey; Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
³ Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
⁴ Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology, Istanbul, Turkey. Electronic address: gdeniz@istanbul.edu.tr.

PMID: 31589897
DOI: 10.1016/j.imlet.2019.10.006

Abstract

Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.

Keywords: IL-22; Multiple sclerosis; NKG2A; NKG2D; NKp44; Natural killer cells.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
CD3 Complex / immunology
CD3 Complex / metabolism
CD56 Antigen / immunology
CD56 Antigen / metabolism
Drug Resistance / immunology
Female
Humans
Immunologic Factors / pharmacology*
Immunologic Factors / therapeutic use
Interferon-beta / pharmacology*
Interferon-beta / therapeutic use
Interleukin-22
Interleukins / blood
Interleukins / immunology
Interleukins / metabolism
Killer Cells, Natural / drug effects
Killer Cells, Natural / immunology*
Killer Cells, Natural / metabolism
Lymphocyte Activation / drug effects
Lymphocyte Subsets / drug effects
Lymphocyte Subsets / immunology*
Lymphocyte Subsets / metabolism
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / blood
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Multiple Sclerosis, Relapsing-Remitting / immunology*
NK Cell Lectin-Like Receptor Subfamily K / immunology
NK Cell Lectin-Like Receptor Subfamily K / metabolism
Treatment Outcome
Young Adult

Substances

CD3 Complex
CD56 Antigen
Immunologic Factors
Interleukins
KLRK1 protein, human
NCAM1 protein, human
NK Cell Lectin-Like Receptor Subfamily K
Interferon-beta